아시아태평양의 급성기 의료 신드로믹 검사 시장 : 분석과 예측(2023-2033년)

“The Asia-Pacific Acute Care Syndromic Testing Market Expected to Reach $2.20 Billion by 2033.”

Introduction to Asia-Pacific Acute Care Syndromic Testing Market

The Asia-Pacific acute care syndromic testing market was valued at $0.78 billion in 2023 and is expected to reach $2.20 billion by 2033, growing at a CAGR of 10.97% between 2023 and 2033. The growth of the market can be attributed to the rising need for early detection of infectious diseases, driven by the growing incidence of such diseases, the occurrence of pandemics, and the identification of new infectious diseases in various regions, exacerbated by global warming.

Market Introduction

The Asia-Pacific (APAC) acute care syndromic testing market is experiencing robust growth and increasing prominence in the region's healthcare landscape. Syndromic testing plays a pivotal role in rapidly diagnosing and managing acute illnesses, offering a timely response to outbreaks and emergencies. This market's expansion is driven by factors such as the rising incidence of infectious diseases, growing awareness of the importance of early diagnosis, and advancements in diagnostic technologies.

In recent years, APAC has witnessed significant investments in healthcare infrastructure and the adoption of innovative diagnostic solutions. These investments have bolstered the acute care syndromic testing market, enabling quicker and more accurate diagnoses in emergency and critical care settings. Furthermore, the ongoing COVID-19 pandemic has underscored the critical role of syndromic testing in public health response, further fueling the demand for such testing solutions across the APAC region.

Market Segmentation:

Segmentation 1: by End User

• Hospitals
• Clinical and Diagnostic Laboratories
• Research and Academic Institutions
• Other End Users

Segmentation 2: by Country

• Japan
• India
• China
• South Korea
• Australia
• Rest-of-Asia-Pacific

How Can This Report Add Value to an Organization?

Growth/Marketing Strategy: Synergistic activities, product launches, and approvals accounted for the maximum number of key developments.

Competitive Strategy: The APAC acute care syndromic testing market has numerous startups paving their way into manufacturing kits, panels, assays, and instruments and entering the market. Key players in the APAC acute care syndromic testing market analyzed and profiled in the study involve established players that offer various kinds of disease-specific panels and multiplex instruments.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

Table of Contents

Executive Summary

1. Markets

• 1.1. Market Scope
  • 1.1.1. Key Questions Answered in the Report
• 1.2. Research Methodology
  • 1.2.1. Acute Care Syndromic Testing Market: Research Methodology
  • 1.2.2. Data Sources
    • 1.2.2.1. Primary Data Sources
    • 1.2.2.2. Secondary Data Sources
  • 1.2.3. Market Estimation Model
  • 1.2.4. Criteria for Company Profiling

2. Market Overview

• 2.1. Overview
• 2.2. Acute Care Syndromic Testing Workflow Analysis
• 2.3. Market Footprint and Growth Potential
• 2.4. Future Potential

3. Industry Insight

• 3.1. Stakeholder's Perspective (N=20)
  • 3.1.1. Physician's Perception
  • 3.1.2. Payor's Perception
  • 3.1.3. Investor's Perception
• 3.2. Legal and Regulatory Framework of the Acute Care Syndromic Testing Market
  • 3.2.1. Regulatory Framework in Asia-Pacific
    • 3.2.1.1. Japan
    • 3.2.1.2. China
    • 3.2.1.3. India
    • 3.2.1.4. South Korea
    • 3.2.1.5. Australia
• 3.3. Product Benchmarking

4. Market Dynamics

• 4.1. Overview
• 4.2. Impact Analysis
• 4.3. Market Drivers
  • 4.3.1. Faster Results Acquired with Syndromic Tests
  • 4.3.2. Increasing Incidence of Infectious Diseases
  • 4.3.3. Overall Reduced Cost of Care Due to Early Diagnosis with Syndromic Testing
  • 4.3.4. Reduced Severe Adverse Effects from Pathogens
• 4.4. Market Challenges
  • 4.4.1. Need for Better Policies with Respect to Acute Care Syndromic Test Reimbursement
  • 4.4.2. Lack of High-Complexity Testing Centres
• 4.5. Market Opportunities
  • 4.5.1. Quick Access to Treatment and Reduced Use of Antibiotics
  • 4.5.2. High Number of Synergistic Activities and Mergers and Acquisitions (M&A) Over the Past Years

5. Acute Care Syndromic Testing Market (By Region), 2022-2033

• 5.1. Overview
• 5.2. Asia-Pacific
  • 5.2.1. Asia-Pacific Acute Care Syndromic Testing Market, By End User
  • 5.2.2. Asia-Pacific Acute Care Syndromic Testing Market, By Country
    • 5.2.2.1. China
    • 5.2.2.2. Japan
    • 5.2.2.3. India
    • 5.2.2.4. Australia
    • 5.2.2.5. South Korea
    • 5.2.2.6. Rest-of-Asia-Pacific

6. Company Profiles

• 6.1. Overview
• 6.2. Acute Care Syndromic Testing Ecosystem Active Players
• 6.3. Seegene Inc.
  • 6.3.1. Company Overview
  • 6.3.2. Role of Seegene, Inc. in the Acute Care Syndromic Testing Market
  • 6.3.3. Financials
  • 6.3.4. Recent Developments
    • 6.3.4.1. Corporate Strategies
    • 6.3.4.2. Business Strategies
  • 6.3.5. Analyst Perspective
• 6.4. SpeeDx
  • 6.4.1. Company Overview
  • 6.4.2. Role of SpeeDX in the Acute Care Syndromic Testing Market
  • 6.4.3. Analyst Perspective